March 06, 2024: Gilead Sciences, Inc. announced new data from three studies evaluating the efficacy and safety profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) for a broad range of people with HIV, including those with HIV/hepatitis B (HBV) coinfection and HIV/tuberculosis (TB) coinfection. These data and other studies supporting the important role of Biktarvy in the HIV treatment landscape were presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI).
Read the full press release here.
Source : Gilead Sciences, Inc.
Related HIV and Co-Infections News
-
[Report] WHO: Efforts to eliminate hepatitis delivers gains but more action needed to meet 2030 targets
-
[Press release] GSK: Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA
-
Eastleigh Voice: Ghana rejects Sh14 billion US health deal over data access concerns
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.